Molecular determinants of prognosis in acute myeloid leukemia (AML) with normal karyotype.

摘要

Considering the heterogeneity of acute myeloid leukemia (AML) with highly variable clinical outcomes and subtypes, current treatment concepts aim to adapt the intensity of therapy to the individual patient's relapse risk. Thus, risk categorization of those 55% of patients with cytogenetic aberrations [1,2] has become one of the baselines for therapeutic decisions in AML. However, in the large subgroup of 45% of patients with normal karyotype, cytogenetics provides no orientation for the categorization of patients. Screening with polymerase chain reaction (PCR)-based methods became highly relevant for the definition of prognosis and for the biological characterization of these cases. Meanwhile, molecular mutations can be identified in >85% of the patients from this subgroup [3].